Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

Market Cap	10.50B -53.3%
Revenue (ttm)	203.92M -30.4%
Net Income	-83.86M
EPS	-0.18
Shares Out	477.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,808,382
Open	23.76
Previous Close	20.94
Day's Range	20.68 - 23.76
52-Week Range	18.98 - 66.66
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyet...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 491
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300204

Financial Performance

In 2025, SHE:300204's revenue was 220.23 million, a decrease of -32.20% compared to the previous year's 324.82 million. Losses were -77.76 million, -46.31% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error